Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2, Pathclear

For Robust Organoid Cultures - Reduced Growth Factor Basement Membrane Extract
Try it on your cultures! Request a Sample of Cultrex RGF BME, Type 2
Catalog # Availability Size / Price Qty
Best Seller
Mouse Intestinal Organoids Cultured in Cultrex RGF BME Type 2_3533-005-02
6 Images
Product Details
Citations (55)
Reviews (5)

Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2, Pathclear Summary

Product Datasheets

You must select a language.


Preparation and Storage

The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended on the product label.
Stability & Storage
Store the unopened product at -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Citations for Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2, Pathclear

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

55 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation
    Authors: Viergever, BJ;Raats, DAE;Geurts, V;Mullenders, J;Jonges, TN;van der Heijden, MS;van Es, JH;Kranenburg, O;Meijer, RP;
    British journal of cancer  2023-12-15
  2. STAT2 Controls Colorectal Tumorigenesis and Resistance to Anti-Cancer Drugs
    Authors: Chiriac, MT;Hracsko, Z;Becker, C;Neurath, MF;
    Cancers  2023-11-15
  3. Functional screening of amplification outlier oncogenes in organoid models of early tumorigenesis
    Authors: Salahudeen, AA;Seoane, JA;Yuki, K;Mah, AT;Smith, AR;Kolahi, K;De la O, SM;Hart, DJ;Ding, J;Ma, Z;Barkal, SA;Shukla, ND;Zhang, CH;Cantrell, MA;Batish, A;Usui, T;Root, DE;Hahn, WC;Curtis, C;Kuo, CJ;
    Cell reports  2023-11-01
  4. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity
    Authors: Prekovic, S;Chalkiadakis, T;Roest, M;Roden, D;Lutz, C;Schuurman, K;Opdam, M;Hoekman, L;Abbott, N;Tesselaar, T;Wajahat, M;Dwyer, AR;Mayayo-Peralta, I;Gomez, G;Altelaar, M;Beijersbergen, R;Gy?rffy, B;Young, L;Linn, S;Jonkers, J;Tilley, W;Hickey, T;Vareslija, D;Swarbrick, A;Zwart, W;
    EMBO molecular medicine  2023-10-30
  5. Single-nucleus RNA sequencing reveals heterogenous microenvironments and specific drug response between cervical squamous cell carcinoma and adenocarcinoma
    Authors: Lin, S;Sun, Y;Cao, C;Zhu, Z;Xu, Y;Liu, B;Hu, B;Peng, T;Zhi, W;Xu, M;Ding, W;Ren, F;Ma, D;Li, G;Wu, P;
    EBioMedicine  2023-10-23
  6. KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer
    Authors: Yao, L;Hao, Q;Wang, M;Chen, Y;Cao, H;Zhang, Q;Yu, K;Jiang, Y;Shao, Z;Zhou, X;Xu, Y;
    Oncogene  2023-10-16
  7. Patient-derived organoid culture in epithelial ovarian cancers-Techniques, applications, and future perspectives
    Authors: Chan, WS;Mo, X;Ip, PPC;Tse, KY;
    Cancer medicine  2023-09-30
  8. Jaw Bone Invasion of Oral Squamous Cell Carcinoma Is Associated with Osteoclast Count and Expression of Its Regulating Proteins in Patients and Organoids
    Authors: de Kort, WWB;Haakma, WE;van Es, RJJ;Gawlitta, D;Driehuis, E;Gansevoort, M;Willems, SM;
    Journal of clinical medicine  2023-09-18
  9. Activation of invasion by oncogenic reprogramming of cholesterol metabolism via increased NPC1 expression and macropinocytosis
    Authors: Skorda, A;Lauridsen, AR;Wu, C;Huang, J;Mrackova, M;Winther, NI;Jank, V;Sztupinszki, Z;Strauss, R;Bilgin, M;Maeda, K;Liu, B;Luo, Y;Jäättelä, M;Kallunki, T;
    Oncogene  2023-07-07
  10. Immune regulatory function of cancer-associated fibroblasts in non-small cell lung cancer
    Authors: Lee, H;Hwang, M;Jang, S;Um, SW;
    Tuberculosis and respiratory diseases  2023-06-22
  11. Creation of EGD-Derived Gastric Cancer Organoids to Predict Treatment Responses
    Authors: McDonald, HG;Harper, MM;Hill, K;Gao, A;Solomon, AL;Bailey, CJ;Lin, M;Barry-Hundeyin, M;Cavnar, MJ;Mardini, SH;Pandalai, PJ;Patel, RA;Kolesar, JM;Rueckert, JA;Hookey, L;Ropeleski, M;Merchant, SJ;Kim, J;Gao, M;
    Cancers  2023-06-02
  12. A histone deacetylase 3 and mitochondrial complex I axis regulates toxic formaldehyde production
    Authors: Wit, N;Gogola, E;West, JA;Vornb�umen, T;Seear, RV;Bailey, PSJ;Burgos-Barragan, G;Wang, M;Krawczyk, P;Huberts, DHEW;Gergely, F;Matheson, NJ;Kaser, A;Nathan, JA;Patel, KJ;
    Science advances  2023-05-19
  13. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors
    Authors: Bhin, J;Paes Dias, M;Gogola, E;Rolfs, F;Piersma, SR;de Bruijn, R;de Ruiter, JR;van den Broek, B;Duarte, AA;Sol, W;van der Heijden, I;Andronikou, C;Kaiponen, TS;Bakker, L;Lieftink, C;Morris, B;Beijersbergen, RL;van de Ven, M;Jimenez, CR;Wessels, LFA;Rottenberg, S;Jonkers, J;
    Cell reports  2023-05-19
  14. ONECUT2 regulates RANKL-dependent enterocyte and microfold cell differentiation in the small intestine; a multi-omics study
    Authors: MV Luna Velez, HK Neikes, RR Snabel, Y Quint, C Qian, A Martens, GJC Veenstra, MR Freeman, SJ van Heerin, M Vermeulen
    Nucleic Acids Research, 2023-02-22;0(0):.  2023-02-22
  15. Mutated axon guidance gene PLXNB2 sustains growth and invasiveness of stem cells isolated from cancers of unknown primary
    Authors: S Brundu, V Napolitano, G Franzolin, E Lo Cascio, R Mastranton, G Sardo, E Cascardi, F Verginelli, S Sarnataro, G Gambardell, A Pisacane, A Arcovito, C Boccaccio, PM Comoglio, E Giraudo, L Tamagnone
    Embo Molecular Medicine, 2023-02-01;0(0):e16104.  2023-02-01
  16. Hypoxia-Driven Changes in a Human Intestinal Organoid Model and the Protective Effects of Hydrolyzed Whey
    Authors: IH de Lange, C van Gorp, KRI Massy, L Kessels, N Kloosterbo, A Bjørnshave, M Stampe Ost, JGMC Damoiseaux, JPM Derikx, WG van Gemert, TGAM Wolfs
    Nutrients, 2023-01-12;15(2):.  2023-01-12
  17. Metabolic Activation of Benzo[a]pyrene by Human Tissue Organoid Cultures
    Authors: AL Caipa Garc, JE Kucab, H Al-Serori, RSS Beck, F Fischer, M Hufnagel, A Hartwig, A Floeder, S Balbo, H Francies, M Garnett, M Huch, J Drost, M Zilbauer, VM Arlt, DH Phillips
    International Journal of Molecular Sciences, 2022-12-29;24(1):.  2022-12-29
  18. AKTIP loss is enriched in ERalpha-positive breast cancer for tumorigenesis and confers endocrine resistance
    Authors: ASN Ng, S Zhang, VCY Mak, Y Zhou, Y Yuen, R Sharma, Y Lu, G Zhuang, W Zhao, HH Pang, LWT Cheung
    Cell Reports, 2022-12-13;41(11):111821.  2022-12-13
  19. Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells
    Authors: A Cañellas-S, C Cortina, X Hernando-M, S Palomo-Pon, EJ Mulholland, G Turon, L Mateo, S Conti, O Roman, M Sevillano, F Slebe, D Stork, A Caballé-Me, A Berenguer-, A Álvarez-Va, N Fenderico, L Novellasde, L Jiménez-Gr, T Sipka, L Bardia, P Lorden, J Colombelli, H Heyn, X Trepat, S Tejpar, E Sancho, DVF Tauriello, S Leedham, CS Attolini, E Batlle
    Nature, 2022-11-09;611(7936):603-613.  2022-11-09
  20. Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins
    Authors: JE van Leeuwe, W Ba-Alawi, E Branchard, J Cruickshan, W Schormann, J Longo, J Silvester, PL Gross, DW Andrews, DW Cescon, B Haibe-Kain, LZ Penn, DMA Gendoo
    Nature Communications, 2022-10-24;13(1):6323.  2022-10-24
  21. Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine
    Authors: A Spanjaard, R Shah, D de Groot, OA Buoninfant, B Morris, C Lieftink, C Pritchard, LM Zürcher, S Ormel, JJI Catsman, R de Korte-G, B Siteur, N Proost, T Boadum, M van de Ven, JY Song, M Kreft, PCM van den Be, RL Beijersber, H Jacobs
    Nucleic Acids Research, 2022-07-22;50(13):7420-7435.  2022-07-22
  22. The metastatic spread of breast cancer accelerates during sleep
    Authors: Z Diamantopo, F Castro-Gin, FD Schwab, C Foerster, M Saini, S Budinjas, K Strittmatt, I Krol, B Seifert, V Heinzelman, C Kurzeder, C Rochlitz, M Vetter, WP Weber, N Aceto
    Nature, 2022-06-22;607(7917):156-162.  2022-06-22
  23. RNA splicing is a key mediator of tumour cell plasticity and a therapeutic vulnerability in colorectal cancer
    Authors: AE Hall, SÖ Pohl, P Cammareri, S Aitken, NT Younger, M Raponi, CV Billard, AB Carrancio, A Bastem, P Freile, F Haward, IR Adams, JF Caceres, P Preyzner, A von Kriegs, MG Dunlop, FV Din, KB Myant
    Nature Communications, 2022-05-19;13(1):2791.  2022-05-19
  24. Human branching cholangiocyte organoids recapitulate functional bile duct formation
    Authors: FJM Roos, GS van Tiende, H Wu, I Bordeu, D Vinke, LM Albarinos, K Monfils, S Niesten, R Smits, J Willemse, O Rosmark, G Westergren, DJ Kunz, M de Wit, PJ French, L Vallier, JNM IJzermans, R Bartfai, H Marks, BD Simons, ME van Royen, MMA Verstegen, LJW van der La
    Cell Stem Cell, 2022-05-05;29(5):776-794.e13.  2022-05-05
  25. Cell-intrinsic Aryl Hydrocarbon Receptor signalling is required for the resolution of injury-induced colonic stem cells
    Authors: K Shah, MR Maradana, M Joaquina D, A Metidji, F Graelmann, M Llorian, P Chakravart, Y Li, M Tolaini, M Shapiro, G Kelly, C Cheshire, D Bhurta, SB Bharate, B Stockinger
    Nature Communications, 2022-04-05;13(1):1827.  2022-04-05
  26. Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis
    Authors: YY Chen, JY Ge, SY Zhu, ZM Shao, KD Yu
    Nature Communications, 2022-02-10;13(1):791.  2022-02-10
  27. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
    Authors: Y Xiao, D Ma, YS Yang, F Yang, JH Ding, Y Gong, L Jiang, LP Ge, SY Wu, Q Yu, Q Zhang, F Bertucci, Q Sun, X Hu, DQ Li, ZM Shao, YZ Jiang
    Cell Research, 2022-02-01;0(0):.  2022-02-01
  28. Efficient and error-free fluorescent gene tagging in human organoids without double-strand DNA cleavage
    Authors: Y Bollen, JH Hageman, P van Leenen, LLM Derks, B Ponsioen, JR Buissant d, I Verlaan-Kl, M van den Bo, LWMM Terstappen, R van Boxtel, HJG Snippert
    PloS Biology, 2022-01-28;20(1):e3001527.  2022-01-28
  29. Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors
    Authors: BH Choi, V Rawat, J Högström, PA Burns, KO Conger, ME Ozgurses, JM Patel, TS Mehta, A Warren, LM Selfors, T Muranen, JL Coloff
    Cell Reports, 2022-01-18;38(3):110278.  2022-01-18
  30. Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection
    Authors: BM Tran, SL Grimley, JL McAuley, A Hachani, L Earnest, SL Wong, L Caly, J Druce, DFJ Purcell, DC Jackson, M Catton, CJ Nowell, L Leonie, G Deliyannis, SA Waters, J Torresi, E Vincan
    International Journal of Molecular Sciences, 2022-01-13;23(2):.  2022-01-13
  31. Adult mouse and human organoids derived from thyroid follicular cells and modeling of Graves' hyperthyroidism
    Authors: J van der Va, L Bosmans, SF Sijbesma, K Knoops, WJ van de Wet, HG Otten, H Begthel, IHM Borel Rink, J Korving, EGWM Lentjes, C Lopez-Igle, PJ Peters, HM van Santen, MR Vriens, H Clevers
    Proceedings of the National Academy of Sciences of the United States of America, 2021-12-21;118(51):.  2021-12-21
  32. A Bioluminescent 3CLPro Activity Assay to Monitor SARS-CoV-2 Replication and Identify Inhibitors
    Authors: C Mathieu, F Touret, C Jacquemin, YL Janin, A Nougairède, M Brailly, M Mazelier, D Décimo, V Vasseur, A Hans, JC Valle-Casu, X de Lamball, B Horvat, P André, M Si-Tahar, V Lotteau, PO Vidalain
    Viruses, 2021-09-12;13(9):.  2021-09-12
  33. Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors
    Authors: C Calandrini, SR van Hooff, I Paassen, D Ayyildiz, S Derakhshan, MEM Dolman, KPS Langenberg, M van de Ven, C de Heus, N Liv, M Kool, RR de Krijger, GAM Tytgat, MM van den He, JJ Molenaar, J Drost
    Cell Reports, 2021-08-24;36(8):109568.  2021-08-24
  34. Ultrastructural analysis of breast cancer patient-derived organoids
    Authors: L Signati, R Allevi, F Piccotti, S Albasini, L Villani, M Sevieri, A Bonizzi, F Corsi, S Mazzucchel
    Cancer Cell International, 2021-08-10;21(1):423.  2021-08-10
  35. ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma
    Authors: F De Bacco, F Orzan, J Erriquez, E Casanova, L Barault, R Albano, A D'Ambrosio, V Bigatto, G Reato, M Patanè, B Pollo, G Kuesters, C Dell'Aglio, L Casorzo, S Pellegatta, G Finocchiar, PM Comoglio, C Boccaccio
    Cell Reports, 2021-07-27;36(4):109455.  2021-07-27
  36. RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways
    Authors: V Gudiño, SÖ Pohl, CV Billard, P Cammareri, A Bolado, S Aitken, D Stevenson, AE Hall, M Agostino, J Cassidy, C Nixon, A von Kriegs, P Freile, L Popplewell, G Dickson, L Murphy, A Wheeler, M Dunlop, F Din, D Strathdee, OJ Sansom, KB Myant
    Nature Communications, 2021-04-20;12(1):2335.  2021-04-20
  37. Culture and analysis of kidney tubuloids and perfused tubuloid cells-on-a-chip
    Authors: L Gijzen, FA Yousef Yen, F Schutgens, MK Vormann, CME Ammerlaan, A Nicolas, D Kurek, P Vulto, MB Rookmaaker, HL Lanz, MC Verhaar, H Clevers
    Nature Protocols, 2021-03-05;0(0):.  2021-03-05
  38. Inhibition of mitochondrial function by metformin increases glucose uptake, glycolysis and GDF-15 release from intestinal cells
    Authors: M Yang, T Darwish, P Larraufie, D Rimmington, I Cimino, DA Goldspink, B Jenkins, A Koulman, CA Brighton, M Ma, BYH Lam, AP Coll, S O'Rahilly, F Reimann, FM Gribble
    Scientific Reports, 2021-01-28;11(1):2529.  2021-01-28
  39. Sox9EGFP defines biliary epithelial heterogeneity downstream of Yap activity
    Authors: DY Tulasi, DM Castaneda, K Wager, CB Hogan, KP Alcedo, JR Raab, AD Gracz
    Cellular and Molecular Gastroenterology and Hepatology, 2021-01-23;0(0):.  2021-01-23
  40. Loss of sphingosine 1-phosphate receptor 3 gene function impairs injury-induced stromal angiogenesis in mouse cornea
    Authors: S Yasuda, T Sumioka, H Iwanishi, Y Okada, M Miyajima, K Ichikawa, PS Reinach, S Saika
    Lab Invest, 2020-11-16;0(0):.  2020-11-16
  41. Single-cell derived tumor organoids display diversity in HLA class I peptide presentation
    Authors: LC Demmers, K Kretzschma, A Van Hoeck, YE Bar-Epraïm, HWP van den To, M Koomen, G van Son, J van Gorp, A Pronk, N Smakman, E Cuppen, H Clevers, AJR Heck, W Wu
    Nat Commun, 2020-10-21;11(1):5338.  2020-10-21
  42. Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells
    Authors: C Donato, L Kunz, F Castro-Gin, A Paasinen-S, K Strittmatt, BM Szczerba, R Scherrer, N Di Maggio, W Heusermann, O Biehlmaier, C Beisel, M Vetter, C Rochlitz, WP Weber, A Banfi, T Schroeder, N Aceto
    Cell Rep, 2020-09-08;32(10):108105.  2020-09-08
  43. Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining
    Authors: P Francica, M Mutlu, VA Blomen, C Oliveira, Z Nowicka, A Trenner, NM Gerhards, P Bouwman, E Stickel, ML Hekkelman, L Lingg, I Klebic, M van de Ven, R de Korte-G, D Howald, J Jonkers, AA Sartori, W Fendler, JR Chapman, T Brummelkam, S Rottenberg
    Cell Rep, 2020-08-25;32(8):108068.  2020-08-25
  44. Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia
    Authors: E Driehuis, N Oosterom, SG Heil, IB Muller, M Lin, S Kolders, G Jansen, R de Jonge, R Pieters, H Clevers, MM van den He
    PLoS ONE, 2020-05-18;15(5):e0231588.  2020-05-18
  45. Slug-expressing mouse prostate epithelial cells have increased stem cell potential
    Authors: Z Kahounová, J Remšík, R Fedr, J Bouchal, A Mi?ková, E Slabáková, L Binó, A Hampl, K Sou?ek
    Stem Cell Res, 2020-05-12;46(0):101844.  2020-05-12
  46. Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages
    Authors: JM Rosenbluth, RCJ Schackmann, GK Gray, LM Selfors, CM Li, M Boedicker, HJ Kuiken, A Richardson, J Brock, J Garber, D Dillon, N Sachs, H Clevers, JS Brugge
    Nat Commun, 2020-04-06;11(1):1711.  2020-04-06
  47. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity
    Authors: C Calandrini, F Schutgens, R Oka, T Margaritis, T Candelli, L Mathijsen, C Ammerlaan, RL van Inevel, S Derakhshan, S de Haan, E Dolman, P Lijnzaad, L Custers, H Begthel, HHD Kerstens, LL Visser, M Rookmaaker, M Verhaar, GAM Tytgat, P Kemmeren, RR de Krijger, R Al-Saadi, K Pritchard-, M Kool, AC Rios, MM van den He, JJ Molenaar, R van Boxtel, FCP Holstege, H Clevers, J Drost
    Nat Commun, 2020-03-11;11(1):1310.  2020-03-11
  48. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening
    Authors: E Driehuis, A van Hoeck, K Moore, S Kolders, HE Francies, MC Gulersonme, ECA Stigter, B Burgering, V Geurts, A Gracanin, G Bounova, FH Morsink, R Vries, S Boj, J van Es, GJA Offerhaus, O Kranenburg, MJ Garnett, L Wessels, E Cuppen, LAA Brosens, H Clevers
    Proc. Natl. Acad. Sci. U.S.A., 2019-12-09;0(0):.  2019-12-09
  49. Oral mucosal organoids as a potential platform for personalized cancer therapy
    Authors: E Driehuis, S Kolders, S Spelier, K Lohmussaar, SM Willems, LA Devriese, R de Bree, EJ de Ruiter, J Korving, H Begthel, JH Van Es, V Geurts, GW He, RH van Jaarsv, R Oka, MJ Muraro, J Vivie, MMJM Zandvliet, APA Hendrickx, N Iakobachvi, P Sridevi, O Kranenburg, R van Boxtel, GJPL Kops, DA Tuveson, PJ Peters, A van Oudena, H Clevers
    Cancer Discov, 2019-05-03;0(0):.  2019-05-03
  50. SH3BP4 Regulates Intestinal Stem Cells and Tumorigenesis by Modulating ?-Catenin Nuclear Localization
    Authors: P Antas, L Novellasde, A Kucharska, I Massie, J Carvalho, D Oukrif, E Nye, M Novelli, VSW Li
    Cell Rep, 2019-02-26;26(9):2266-2273.e4.  2019-02-26
  51. Neutrophils escort circulating tumour cells to enable cell cycle progression
    Authors: BM Szczerba, F Castro-Gin, M Vetter, I Krol, S Gkountela, J Landin, MC Scheidmann, C Donato, R Scherrer, J Singer, C Beisel, C Kurzeder, V Heinzelman, C Rochlitz, WP Weber, N Beerenwink, N Aceto
    Nature, 2019-02-06;0(0):.  2019-02-06
  52. Novel Chimeric Gene Therapy Vectors Based on Adeno-Associated Virus and Four Different Mammalian Bocaviruses
    Authors: J Fakhiri, MA Schneider, J Puschhof, M Stanifer, V Schildgen, S Holderbach, Y Voss, J El Andari, O Schildgen, S Boulant, M Meister, H Clevers, Z Yan, J Qiu, D Grimm
    Mol Ther Methods Clin Dev, 2019-01-18;12(0):202-222.  2019-01-18
  53. Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion
    Authors: DM Brix, SA Tvingsholm, MB Hansen, KB Clemmensen, T Ohman, V Siino, M Lambrughi, K Hansen, P Puustinen, I Gromova, P James, E Papaleo, M Varjosalo, J Moreira, M Jäättelä, T Kallunki
    Oncogene, 2019-01-08;0(0):.  2019-01-08
  54. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.
    Authors: Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, Balgobind A, Wind K, Gracanin A, Begthel H, Korving J, van Boxtel R, Duarte A, Lelieveld D, van Hoeck A, Ernst R, Blokzijl F, Nijman I, Hoogstraat M, van de Ven M, Egan D, Zinzalla V, Moll J, Boj S, Voest E, Wessels L, van Diest P, Rottenberg S, Vries R, Cuppen E, Clevers H
    Cell, 2017-12-07;172(1):373-386.e10.  2017-12-07
  55. AGE-RAGE interaction in the TGF?2-mediated epithelial to mesenchymal transition of human lens epithelial cells.
    Authors: Cibin T Raghavan, Ram H Nagaraj
    Glycoconjugate Journal, 2016-06-04;0(0):1573-4986.  2016-06-04


  1. What kinds of tumor cells or biopsy specimens grow in vivo with Cultrex® BME?

    • Many cell lines and tumor biopsy specimens (usually cut into small fragments) have been found to grow in vivo when implanted with Cultrex® BME. These include melanoma, intestinal, prostate, breast, lung, renal, and liver cancers as well as the 3T3 mouse embryonic fibroblast cell line.

  2. How does Cultrex® Basement Membrane Extract (BME) promote cell differentiation?

    • All epithelial and endothelial cells are in contact with a basement membrane matrix on at least one of their surfaces. By providing them with their natural matrix in vitro as a substrate for the cells that provides biological cues, the cells can assume a more physiological morphology (i.e. correct shape) and begin expression of cell-lineage specific proteins. Two-dimensional plastic surfaces, in combination with serum-containing media, cause cells to flatten, proliferate and de-differentiate.

  3. How should Cultrex Basement Membrane Extract (BME) be stored and handled?

    • Cultrex BME should be stored at or below -20°C for optimal stability. Preparation of working aliquots is recommended. Cultrex BME should be thawed overnight on ice at 4°C, however long term storage at 4°C is not recommended. Freeze/thaw cycles and gel-liquid phase transitions should be avoided, since they can compromise product integrity.

  4. What is the Tube Formation Assay?

    • The Tube Formation Assay is based on the ability of endothelial cells to form three-dimensional capillary-like tubular structures when cultured on a hydrogel of reconstituted basement membrane, such as Cultrex Basement Membrane Extract (BME).

  5. What are the advantages of the Tube Formation Assay?

    • The Tube Formation Assay is the most widely used in vitro angiogenesis assay. The assay is rapid, inexpensive and quantifiable. It can be used to identify potentially angiogenic and anti-angiogenic factors, to determine endothelial cell phenotype, and to study pathways and mechanisms involved in angiogenesis. It can be performed in a high throughput mode to screen for a large number of compounds.

  6. What cell types can be used in the Tube Formation Assay?

    • The Tube Formation Assay is specific for endothelial cells, either primary cells or immortalized cell lines. Only endothelial cells form capillary-like structures with a lumen inside. Other endothelial cell types form other structures.

  7. What are the variables associated with the Tube Formation Assay?

    • The major variables associated with tube formation are composition of the Cultrex Basement Membrane Extract (BME) hydrogel, thickness of the hydrogel, cell density, composition of angiogenic factors in the assay medium, and assay period.

  8. Which Cultrex Basement Membrane Extract (BME) should I use for the Tube Formation Assay?

    • Cultrex Reduced Growth Factor BME (RGF BME) is generally used for testing compounds that promote angiogenesis because formation of capillary-like structures (tubes) is significantly less compared to non-growth factor reduced varieties of Cultrex BME. The Cultrex In Vitro Angiogeneis Assay (Tube Formation) includes a qualified production lot of Cultrex RGF BME that exhibits reduced background tube formation in the absence of angiogenic factors.

  9. How do I reduce spontaneous formation of tubular structures on Cultrex BME in the absence of angiogenic factors?

    • Primary endothelial cells, such as Human Umbilical Vein Endothelial Cells (HUVECs) form capillary-like structures in the absence of added angiogenic factors less often than immortalized endothelial cells. Generally, reducing the number of cells per cm2 plated onto Cultrex BME will result in less background or spontaneous tube formation. Titrate the number of cells and find optimal conditions for your specific cell line. When endothelial cells fully form capillary structures in response to angiogenic activators, but not in their absence, you may proceed.

  10. Does Cultrex BME, Catalog # 3533-005-02, affect fluorescence readings when Alamar Blue is used for final readout of assay? 

    • BME is known to have autofluorescence, but if appropriate controls are evaluated, background can be successfully subtracted. A BME only control well with no cells should be used to subtract the background fluorescence.

View all FAQs

Reviews for Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2, Pathclear

Average Rating: 5 (Based on 5 Reviews)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2, Pathclear?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2, Pathclear
By Anonymous on 06/18/2022

dissolve it on ice, and don't put it outside for too not time

Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2, Pathclear
By Anonymous on 02/21/2022

Aortic sprouting assay: mouse aortic ring cultured in a 48-well plate and imaged in an inverted microscope after 5 days.

Results are very consistent with this BME (used one layer under and another on top of the aortic ring).

Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2, Pathclear
By Anonymous on 04/13/2021

Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2, Pathclear
By Anonymous on 12/09/2020

We are using the BME at a final dilution of 1/30 for the maintenance of iPSC and differentiation into endoderm as well as mesoderm lineages. Attachment, growth, and differentiation of our iPSC is consistent, and we observed only minor variations between different lots.

Cultrex PathClear Reduced Growth Factor BME (2 x 5 mL)
By wenyi wu on 06/01/2018
Application: Cell migration/motility
Reason for Rating: it can form a very nice tube in our control group within 6-8 hour.